PTGS2 and metabolic dysfunction-associated steatotic liver disease: The administration of VSL#3, a mixture of three genera of bacteria, limits inflammatory injury in the liver of NAFLD rats by inhibiting the production of tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), and cyclooxygenase 2 (COX-2) [18].